Positive and Negative Regulation of Prostate Stem Cell Antigen Expression by Yin Yang 1 in Prostate Epithelial Cell Lines

Shuai Tang¹23, Meenu Mishra²5, Donna P. Frazier², Miranda L. Moore², Kazushi Inoue²34, Rajendar Deora⁵, Guangchao Sui⁴,⁵, Purnima Dubey¹5

¹Molecular Pathology Graduate Program, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, ²Department of Pathology-Tumor Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, ³Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, ⁴Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, ⁵Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America

Abstract

Prostate cancer is influenced by epigenetic modification of genes involved in cancer development and progression. Increased expression of Prostate Stem Cell Antigen (PSCA) is correlated with development of malignant human prostate cancer, while studies in mouse models suggest that decreased PSCA levels promote prostate cancer metastasis. These studies suggest that PSCA has context-dependent functions, and could be differentially regulated during tumor progression. In the present study, we identified the multi-functional transcription factor Yin Yang 1 (YY1) as a modulator of PSCA expression in prostate epithelial cell lines. Increased YY1 levels are observed in prostatic intraepithelial neoplasia (PIN) and advanced disease. We show that androgen-mediated up-regulation of PSCA in prostate epithelial cell lines is dependent on YY1. We identified two direct YY1 binding sites within the PSCA promoter, and showed that the upstream site inhibited, while the downstream site, proximal to the androgen-responsive element, stimulated PSCA promoter activity. Thus, changes in PSCA expression levels in prostate cancer may at least partly be affected by cellular levels of YY1. Our results also suggest multiple roles for YY1 in prostate cancer which may contribute to disease progression by modulation of genes such as PSCA.

Introduction

Prostate cancer is a heterogeneous disease arising from genetic events such as Pten deletion which result in tumor initiation [1,2,3]. Epigenetic gene regulation may augment tumor initiation in conjunction with the oncogenic signal and is known to modulate tumor progression [4]. Thus it is critical to understand transcriptional and translational control mechanisms which influence tumor progression, as these pathways may provide novel therapeutic opportunities for advanced disease.

Prostate Stem Cell Antigen (PSCA) is a GPI-anchored cell surface protein [5] and is a marker of the transiently amplifying cell population within prostate epithelium [6]. PSCA is also expressed in epithelial cells of various organs including the kidney, bladder, stomach and pancreas [7]. PSCA over-expression is reported in a subset of prostate cancers at all stages from PIN to metastatic disease [8]. Although this protein has been considered as a target for therapy [8,9] and imaging [10] of prostate cancer, its function is still unknown. Studies of human prostate cancers suggest that expression of PSCA in PIN is a predictor of later development of invasive adenocarcinoma [11]. In addition our studies in a murine prostate cancer model showed that loss of PSCA promotes tumor metastasis [12]. Together, these data suggest that changes in PSCA expression levels may alter tumor development and progression.

PSCA is an androgen-responsive gene and expression in the prostate is modulated in response to systemic changes in androgen, through interaction of androgen receptor (AR) with an androgen-responsive element (ARE) [13]. However, other control mechanisms must be involved, since PSCA is expressed in castration-resistant prostate cancer [3], and in androgen-insensitive organs such as the kidney, stomach, pancreas and bladder [7].

The transcription factor Yin Yang 1 (YY1) [14] is expressed in normal tissues and is up-regulated in various cancers including prostate cancer, with positive and negative regulatory effects on gene expression [15,16]. Elevated YY1 expression is correlated...
with development of PIN and advanced prostate cancer [15,17,18]. Although the function of YY1 in prostate cancer is not fully known, it was reported recently that YY1 forms a complex with AR, which together binds to the ARE within the PSA promoter, stimulating gene expression [19]. Thus, YY1 has a role in epigenetic regulation of prostate cancer genes.

In this study, we demonstrated that androgen-mediated stimulation of PSCA expression requires YY1. In addition, we identified two direct YY1 binding sites within the upstream region of the PSCA gene. Deletion analysis showed that the upstream site represses PSCA promoter activity, while the downstream site stimulates promoter activity. Furthermore, knockdown of YY1 in prostate cancer cell lines increased endogenous PSA message, suggesting that changes in PSA message levels during prostate cancer progression may be at least partially regulated by YY1.

Materials and Methods

Cell lines
Pen P8 and Pen CaP8 cells were provided by Dr. Hong Wu (UCLA) and maintained as described [20]. LNCaP cells [21] provided by Dr. Owen Witte (UCLA) and PC-3 cells (ATCC, [22]) were maintained in RPMI with 10% fetal bovine serum. HEK293T cells [23] were a gift of Dr. Owen Witte.

PSCA promoter constructs
The murine PSCA genomic clone was a gift of Dr. Owen Witte. The −4.5 kb EcoR1 promoter fragment was isolated by restriction digestion from pBluescript and cloned into the EcoR1 site of pGLuc-4.5 kb. To generate site-specific mutations of the YY1 binding sites, a 2 kb BamHI fragment of the promoter isolated from pGLuc−4.5 kb was sub-cloned into pBluescript. Mutations were performed essentially as described in the Stratagene QuickChanger PCR kit using the following primers: mPSCA Site 1 primer: 5′-GGGTTTATTCTCCAGAACCCACGCCGTGGA-C CATAGTGAGGAGG-3′ and mPSCA Site 2 primer: 5′-CC- C TGGACACGGCTGAGTGATCATC′. The mutated nucleotides are underlined.

A MluII restriction site was introduced in mPSCA Site 1 and a Sal I site was introduced in mPSCA Site 2 (restriction sites bolded; ATG and stop codon are italicized), digested with EcoRI and ligated into the unique EcoRI site of the pVL1392 baculovirus expression vector (BD Biosciences). The HA-YY1 cDNA was PCR amplified from pcDNA3.1-HA-YY1 using Pfu Ultra DNA polymerase (Stratagene, Agilent Technologies) with sense primer 5′-AGTCCGGGAATTCCGCAAGCTT- GTGCTACCCCATACGATTCT3′ and antisense primer 5′- AGTCCGGGAATTCCGCAAGCTT- GTGCTACCCCATACGATTCT3′. The resulting PCR product was cloned into the unique MluI site of the pVL1392 baculovirus transfer vector (BD Biosciences). HA-YY1 baculovirus stock was prepared following manufacturer’s instructions by co-transfecting Spodoptera frugiperda Sf9 cells with 4 μg of pVL1392-HA-YY1 and 0.5 μg of baculovirus DNA (Bac Biosciences) per 2 × 10^8 cells/60 mm. Sf9 cells were maintained in Grace’s medium containing 10% FBS, Yeastolate, lactalbumin hydrolysate, and gentamicin (Invitrogen). Low titer stock was harvested and 40 μL was infected into 1 × 10^9 Sf9 cells for amplification, and high titer HA-YY1 baculovirus stock was harvested and stored at 4°C until use. For HA-YY1 protein expression, 500 μL of the HA-YY1 baculovirus stock was used to infect 1 × 10^7 Sf9 cells/10 mL. Forty-eight hours later, the infected cells were harvested in EBC buffer plus protease inhibitors [24]. HA-YY1 was isolated from the Sf9 lysate using EZView Red Anti-HE Affinity Gel (Sigma) according to manufacturer’s instructions and analyzed by SDS-PAGE. Protein concentration was determined using protein standards (BioRad). HA-YY1 was verified by Western blotting with monoclonal YY1 antibody (H-10, Santa Cruz Biotechnology).

Production and purification of recombinant YY1 protein
The HA-YY1 cDNA was PCR amplified from pcdNA3.1-HA-YY1 using Pfu Ultra DNA polymerase (Stratagene, Agilent Technologies) with sense primer 5′-AGTCCGGGAATTCCGCAAGCTT-GTGCTACCCCATACGATTCT3′ and antisense primer 5′-AGTCCGGGAATTCCGCAAGCTT-GTGCTACCCCATACGATTCT3′. The resulting PCR product was cloned into the unique MluI site of the pVL1392 baculovirus expression vector (BD Biosciences). HA-YY1 baculovirus stock was prepared following manufacturer’s instructions by co-transfecting Spodoptera frugiperda Sf9 cells with 4 μg of pVL1392-HA-YY1 and 0.5 μg of baculovirus DNA (Bac Biosciences) per 2 × 10^8 cells/60 mm. Sf9 cells were maintained in Grace’s medium containing 10% FBS, Yeastolate, lactalbumin hydrolysate, and gentamicin (Invitrogen). Low titer stock was harvested and 40 μL was infected into 1 × 10^9 Sf9 cells for amplification, and high titer HA-YY1 baculovirus stock was harvested and stored at 4°C until use. For HA-YY1 protein expression, 500 μL of the HA-YY1 baculovirus stock was used to infect 1 × 10^7 Sf9 cells/10 mL. Forty-eight hours later, the infected cells were harvested in EBC buffer plus protease inhibitors [24]. HA-YY1 was isolated from the Sf9 lysate using EZView Red Anti-HE Affinity Gel (Sigma) according to manufacturer’s instructions and analyzed by SDS-PAGE. Protein concentration was determined using protein standards (BioRad). HA-YY1 was verified by Western blotting with monoclonal YY1 antibody (H-10, Santa Cruz Biotechnology).

Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as described previously [25,26]. A 500-bp fragment encompassing each binding site was generated by PCR and cloned into pBluescript using the KpnI and EcoRI enzymes in the primer sequences. The plasmids were first digested with Kpn I, end-labeled with γ-32P-dATP using T4 polynucleotide kinase (New England Biolabs), and then digested with EcoRI. Excess unincorporated radioactivity was removed by purification through a G-50 quick-spin column (GE Healthcare). Reactions containing the radiolabeled fragment, purified HA-YY1 protein and 1× binding buffer [10 nM Tris-HCl (pH 7.8), 2 mM MgCl2, 50 mM NaCl, 1 mM dithiothreitol, 100 ng of bovine serum albumin, 10% glycerol] in 20 μL volume, were incubated at 37°C for 15 min to allow DNA-protein binding. The samples were electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography.

Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were carried out as described previously [27]. Precipitated DNA was analyzed by PCR using primers specific for the human and murine upstream and downstream YY1 binding sites. Human PSCA downstream site (hPSCA1) primers: FWD-5′-GTGTTGCGCCCTTGGTTAGC-GC-3′ and REV-5′-GGCCCTGTGAAATGCGCACTC-3′; murine upstream site (mPSCA2) primers: FWD-5′-GGGCCGTGGAAGGTGAGTCT-3′ and REV-5′-GGGCCGTGGAAGGTGAGTCT-3′. Murine PSCA downstream site (mPSCA1) primers: FWD-5′-GGGGAACCGGAGCCTTGGCCCTTTTAA-3′ and REV-5′-CCCAAGTGGCCCTTTGCTGAGCGC-3′; murine upstream site (mPSCA2) primers: FWD-5′-CCCAAGTGGCCCTTTGCTGAGCGC-3′ and REV-5′-CCCAAGTGGCCCTTTGCTGAGCGC-3′. Beta actin primers used as negative control were: FWD-5′-CAGACCTTACCATTCGAC-3′ and REV-5′-TTCGACATCTCTACCTAC-3′. PCR products were analyzed on a 1% agarose gel and visualized by ethidium bromide.

Lentiviral infection
LNCaP or PC3 cells were plated in 6-well plates (Corning) at a density of 1 × 10^5 cells/well, 12–18 hours prior to infection in their respective culture medium. The next day, concentrated lentivirus was added to the well at a 1:100 dilution with 8 μg/ml polybrene (Sigma). The virus was removed after 8–15 hours of incubation and fresh medium was added to the wells. Cells were trypsinized and harvested for analysis 48–60 hours following infection.

R1881 stimulation
For stimulation with synthetic androgen, cells were cultured for 24 hr in Pen medium prepared using phenol-red free DMEM with 10% charcoal-stripped serum. Androgen analog R1881 stock was added to the cells at a concentration of 10−7 M, and the cells were incubated for 12–18 hours prior to analysis.
(10 nM final in DMSO) or DMSO alone was added for an additional 24 hr of culture [19].

**Transient transfection**

HEK293T cells were transiently transfected in triplicate with 3 μg of DNA (2.5 μg pGLuc2 plasmids containing the intact promoter or the site-specific mutations, with 0.5 μg dsRed-containing plasmid for transfection control) using GeneJuice (Novagen) and the manufacturer’s protocol. Expression of dsRed and luciferase activity was determined 72 hr post-transfection.

**Quantitative real-time PCR analysis**

RNA was extracted from prostate cancer cell lines using the Qiagen RNEasy isolation kit and manufacturer’s instructions. Human and murine PSCA message levels were determined using TaqMan Gene Expression assay kits (Applied Biosystems) and following manufacturer’s instructions. Analysis was performed on an ABI 7700 real-time PCR machine, using the relative quantitation method. Normalization was performed using human GAPDH and murine beta actin, also using TaqMan Gene Expression assay kits.

**Luciferase assays**

Infected cells were lysed in Passive Lysis Buffer (Promega) and Gaussia luciferase activity was assessed using 2 μg/ml coelenterazine in DMEM as a substrate, and read in a luminometer. Luciferase activity was normalized to the percentage of dsRed-expressing cells in each well.

**Flow cytometry**

Cell surface PSCA protein levels were quantified by staining cell lines with rabbit polyclonal anti-PSCA antibody (0.2 μg/ml, Santa Cruz Biotechnology) followed by goat anti-rabbit-APC (1:1000) and analyzed on a BD FacsCalibur instrument using CellQuest Pro® software. Expression of dsRed in live cells was analyzed on the FACSCalibur.

**Results**

Recombinant YY1 directly binds to predicted binding elements in the human and murine PSCA promoters

PSCA responses to systemic androgen are mediated through an androgen-responsive element (ARE) in the human and murine promoter regions. However, regulatory mechanisms which modulate PSCA expression in the prostate in the absence of androgen, or in other epithelial tissues, are undefined. In order to identify other putative control mechanisms, we scanned the human and murine PSCA sequences using the TFSearch algorithm [28] to determine whether other transcription factors with a role in epithelial cancer development and progression may also interact with the PSCA promoter. A previous study showed that expression in a transgenic mouse of a Green Fluorescent Protein (GFP) reporter gene behind ~9 kb PSCA upstream region replicated the expression pattern of endogenous PSCA [29]. Subsequent work showed that the shorter ~6 kb upstream region [13] maintained promoter activity and specificity and contained the ARE. Therefore, we limited our analysis to the ~6 kb regions of the human and murine PSCA promoters.

![Figure 1. Schematic diagram of predicted YY1 binding sites in the human and murine PSCA promoter. A. Two YY1 binding sites (shown as diamonds) predicted by the TFSearch algorithm are located upstream of an ARE (triangles) in both the human and murine promoter; B. Nucleotide sequence alignment of these sites to consensus YY1 binding sites [30] shows significant homology. doi:10.1371/journal.pone.0035570.g001](image-url)
We identified two predicted YY1 binding sites within both of these sequences. Figure 1A shows the relative location of the binding sites compared to the previously identified ARE within these promoters [13], and in relation to the transcription initiation site previously identified for the hPSCA promoter. The nucleotide sequence of the sites and homology to the consensus YY1 site [30] is shown in Figure 1B. The downstream site, mPSCA1 is adjacent to the ARE. No putative ARE was identified adjacent to the upstream site, mPSCA2.

To determine whether both of the putative YY1 binding sites in the murine PSCA promoter bound purified YY1 in vitro, we conducted EMSA analysis. We used recombinant human HA-tagged YY1 for our studies, since human and murine YY1 proteins share 97% similarity, with 100% identity in their zinc finger DNA-binding domains. Recombinant HA-YY1 was produced in SF9 insect cells, purified using the HA tag (Figure 2A) and verified by Western blot (Figure 2B). Binding of the recombinant protein to the downstream predicted site (mPSCA1) (Figure 2C) and the upstream site (mPSCA2) (Figure 2D) was observed and was competed by non-radioactive specific DNA but not by poly dI-dC as non-specific competitor. At higher concentrations of SF9-YY1 protein, there was no change in the mobility of the DNA-protein complex for mPSCA2. Therefore fewer lanes are shown in Figure 2C than in Figure 2D.

Chromatin immunoprecipitation assay using anti YY1 antibody detects human and murine PSCA upstream sequences from prostate cancer cell lines

To determine interaction of YY1 with the PSCA promoter in vivo, we conducted chromatin immuno-precipitation analysis (ChIP) using human and murine prostate cancer cell lines. LNCaP cells are a human androgen-dependent prostate cancer cell line

![Figure 2. Recombinant YY1 protein binds specifically to murine PSCA promoter fragments. A. Coomassie stained polyacrylamide gel shows purity of HA-tagged YY1 protein produced in Sf9 insect cells. B. Western blot using anti-HA antibody confirms size and integrity of recombinant YY1. C. EMSA analysis using a 500 bp fragment including the downstream YY1 binding site (mPSCA1) in the murine promoter shows specific binding of YY1 to this fragment. Specific competitor is unlabeled promoter fragment and non-specific competitor is poly dIdC. D. EMSA analysis using a 500 bp fragment including the upstream YY1 binding site (mPSCA2) in the murine promoter shows specific binding of YY1 to this fragment. Specific competitor is unlabeled promoter fragment and non-specific competitor is poly dIdC.](#)
YY1 is required for R1881-mediated stimulation of PSCA expression

The binding of AR to ARE sequences within promoters can either stimulate or inhibit gene transcription and is dependent on the cofactors recruited to the site. It was recently reported by one of us [19] that AR stimulation of PSA transcription requires YY1, and is mediated by an AR-YY1 protein complex which binds to the ARE. mPSCA1 is separated from the previously defined AREs within the PSCA promoter by approximately 200 nucleotides. To determine whether AR-mediated stimulation of PSCA expression also required YY1, we investigated the effect of YY1 knockdown on endogenous PSCA protein and message levels.

Pten CaP8 and Pten CaP2 cells are cell lines derived from the tumors of prostate-specific Pten knockout mice [20]. Pten CaP8 and Pten CaP2 cells were cultured in androgen-depleted conditions for 48 hours. The androgen analog R1881 or vehicle was added to the cells and cell surface PSCA expression was determined 48 hours later by flow cytometry. PSCA expression was increased following R1881 stimulation of Pten CaP8 and Pten CaP2 cells (Figure 5A, upper panels). To determine whether knockdown of endogenous YY1 influenced stimulation of PSCA protein levels by R1881, the cells were infected with a lentivirus expressing YY1siRNA [33] and GFP or with GFP-expressing virus alone followed by androgen deprivation and stimulation of the infected cells. Infection with the YY1 knockdown construct resulted in a 50% reduction in cell-surface PSCA levels following R1881 stimulation compared with vector infected Pten CaP8 cells (Figure 5A, lower panel), while YY1 knockdown abrogated the increase in cell-surface PSCA levels in Pten CaP2 cells. Knockdown of YY1 was achieved with greater than 90% efficiency in both cells (Figure 5B). Thus, YY1 expression is necessary for androgen-mediated stimulation of PSCA expression. Both Pten CaP2 and Pten CaP8 cells die 96 hours following YY1siRNA infection (data not shown) suggesting that YY1 knockdown adversely affects viability of these cells.

To determine whether the change in PSCA protein was a result of transcriptional modulation, Pten CaP2 cells infected with the YY1siRNA construct, or dsRed vector alone, were evaluated for changes in endogenous PSCA message levels. Real-time quantitative PCR analysis showed that PSCA message levels were reduced by knockdown of YY1 (Figure 5C), and a slight, but not statistically significant increase \( (p = 0.09) \) was observed following R1881 stimulation of the YY1siRNA infected cells. This increase in PSCA message could be the result of better cell viability in hormone-replete medium, or stimulation of expression from the residual YY1 present in the cells.

Mutation of the direct YY1 binding sites modulates mPSCA promoter activity

YY1 binding to promoters can either inhibit or stimulate transcription [31,32]. To determine whether YY1 binding positively or negatively regulated PSCA promoter activity, we generated reporter constructs where 4.5 kb of the mPSCA promoter controlled expression of the Gaussia luciferase reporter. Site-specific mutations of mPSCA1 and mPSCA2 were introduced alone or together into the -4.5 kb promoter. HEK293T cells were transiently transfected with the reporter constructs along with a dsRed-expressing vector to determine transfection efficiency. Transfected cells were analyzed 72 hr later. Mutation of three nucleotides in mPSCA2 increased luciferase activity several hundred-fold compared to the intact construct (Figure 4). In contrast, mutation of mPSCA1 by changing 3 nucleotides repressed promoter function (Figure 4). Mutation of both binding sites generated intermediate luciferase activity, showing opposing functions for the two binding sites. Thus, YY1 may exert dual control on PSCA promoter expression.
YY1 inhibits PSCA expression in androgen-independent prostate cancer cells

To determine whether YY1 also modulates human PSCA expression, we determined the effect of YY1 knockdown in an androgen-dependent human prostate cancer cell line, LNCaP, and an androgen-independent human prostate cancer cell line, PC-3. LNCaP cells were infected with YY1siRNA lentivirus or dsRed control virus, and RNA was purified 72 hr later. There was no significant change in human PSCA message levels in LNCaP cells (Figure 6A), despite nearly 100% infection of the cells (not shown) and efficient knock down of YY1 protein (Figure 6B). These results suggest that in a cell line with functioning androgen receptor, the positive and negative effects of YY1 are cancelled out by knockdown of YY1, resulting in no net change in PSCA expression levels.

To determine whether YY1 regulates PSCA expression without the contribution of AR, the effect of YY1 knockdown was evaluated in PC-3 cells, which contain mutant AR. PC-3 cells were infected with the YY1siRNA lentivirus or dsRed control virus, and RNA was purified 72 hr later. Quantitative RT-PCR analysis showed that infection with YY1siRNA significantly increased endogenous PSCA expression in PC-3 cells (Figure 6C). Nearly 100% of the cells were infected (data not shown) resulting in effective knockdown of YY1 protein expression (Figure 6D). These data suggest that YY1 represses PSCA expression in androgen-independent prostate cancer cells.

Discussion

Levels of PSCA protein and message vary in prostate cancer and may be affected by different modifiers during tumor progression. Previous work showed that PSCA expression is reduced after castration [29,34], and increased when androgen is provided exogenously, likely due to binding of androgen to an ARE within the PSCA promoter [13]. In this study, we demonstrated that the multifunctional transcriptional factor YY1 binds directly to the PSCA promoter and regulates PSCA expression in androgen-dependent and independent cell lines. The increase in cell surface PSCA protein levels following stimulation with a synthetic androgen analog was regulated by YY1. We observed a partial reduction in cell surface PSCA levels in Pten CaP8 cells following YY1 knockdown and R1881 stimulation. The low levels of YY1 still present in the cells may be sufficient for interaction with AR and stimulation of PSCA.
expression. Alternately, AR may partially stimulate expression alone or in conjunction with other cofactors. Complete inhibition of PSCA expression in Pten CaP2 cells after YY1 knockdown suggests strong dependence on YY1 for R1881-mediated stimulation of PSCA expression. An earlier report showed that an AR-YY1 complex bound to the ARE in the human PSA promoter, and stimulated transcription [19]. Our in vitro data showed that promoter activity was abrogated when the mPSCA1 site adjacent to the ARE was mutated, suggesting that YY1 binding to this site mediates upregulation of PSCA together with AR. Our results do not exclude the possibility that an AR-YY1 complex is also binding to the ARE, and optimal stimulation of PSCA expression by AR may require both of these interactions.

Figure 5. Knockdown of YY1 reduces androgen-mediated up-regulation of PSCA on the cell surface. A. Pten CaP8 and Pten CaP2 cells were incubated in hormone-depleted medium for 48 hours and then treated with 10 nM R1881 or vehicle (upper panels). Pten CaP2 and Pten CaP8 cells were infected with a lentivirus expressing YY1 specific siRNA or dsRed expression virus as control. Cells were then androgen deprived and treated with 10 nM R1881 for 48 hours (lower panels). Cell surface PSCA expression was determined by FACS using a polyclonal rabbit anti PSCA antibody. B. Expression of YY1 in Pten CaP8 and Pten CaP2 cells infected with YY1 siRNA expressing or control lentivirus was determined by Western blot. The blot was re-probed with anti-β-actin as a loading control. C. Quantitative real-time PCR analysis for PSCA expression was conducted on RNA extracted from Pten CaP2 cells in A.
Our results provide a potential explanation for the varied expression levels of PSCA in the different stages of prostate cancer. YY1 expression is elevated in PIN and intermediate stage disease [15,18], and its interaction with AR may result in increased PSCA expression in PIN and well-differentiated cancers. Similarly, changes in YY1 levels together with changes in systemic androgen may modulate PSCA expression during tumor progression.

Increased reporter gene activity from the promoter construct with mutation of the distal YY1 binding site, mPSCA2, suggested that this is an inhibitory site. In an androgen-independent cell line, PC-3, knockdown of YY1 increased PSCA message. Although we cannot exclude the possibility that other mutations acquired by PC-3 cells may contribute to the downregulation of PSCA by YY1, our data strongly suggest that YY1 may inhibit PSCA expression in advanced prostate cancer. In murine and human androgen-dependent cell lines, YY1 knockdown did not increase endogenous PSCA message. However, by knocking down YY1 levels, we also prevented stimulation of PSCA transcription by AR. Thus, the potential increase in transcription by preventing YY1 binding to the inhibitory sites may be offset by the reduction in AR-mediated transcription.

The direct binding of YY1 to gene regulatory sequences can be either stimulatory or inhibitory, and depends on the associated recruited cofactors [31,32]. Here we show that YY1 can both inhibit and stimulate the same promoter through interaction with different YY1 binding sites in the promoter, an observation also made previously for other promoters [35,36]. Thus, regulation of PSCA by YY1 is likely to be context-dependent and modulated during tumor progression.

Although PSCA upregulation by androgen was defined some time ago, the mechanism by which PSCA expression is decreased in a subset of prostate cancers and in other epithelial cancers is unknown. Our data suggest repression of PSCA promoter activity by YY1 as one potential mechanism for reduced PSCA expression. The earlier description of regulation of the PSA promoter by an YY1-AR complex [19], together with the present work, suggests that YY1 may influence prostate cancer progression by regulation of at least two prostate cancer genes.

The role of YY1 in non-androgen dependent epithelial cancers such as bladder and pancreas, where PSCA is also expressed, is presently unknown. Elevated YY1 levels in these cancers may decrease PSCA levels by direct binding of YY1 to the inhibitory site in the promoter. Clinical data show that PSCA is up-regulated in bladder carcinoma in situ and down-regulated in invasive and advanced disease [37]. Recently, a single nucleotide polymorphism which reduced PSCA expression in human bladder [38] and gastric cancer [39] was associated with more aggressive disease. Down-regulation of PSCA expression by YY1 may similarly reduce PSCA expression and promote disease progression in these cancers. Further exploration of PSCA regulation by YY1 in other epithelial cancers will help to elucidate this mechanism.

Acknowledgments

We acknowledge the Cell and Viral Vector Core Laboratory and the Flow Cytometry Shared Resource of the Comprehensive Cancer Center, WFSM. We thank Neha Chatrath for technical assistance.

Author Contributions

Conceived and designed the experiments: ST PD GS KI RD. Performed the experiments: ST MM MLM DPF PD. Analyzed the data: ST PD. Contributed reagents/materials/analysis tools: GS RD KI. Wrote the paper: ST PD.
References

1. Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, et al. (2004) Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci U S A 101: 1725–1730.

2. Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS (1998) Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 58: 3652–5653.

3. Wang S, Gao J, Le Q, Rovzengurt N, Pritchard C, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209–221.

4. Dobosy JR, Roberts JL, Fu VX, Jarrard DF (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177: 1722–1730.

5. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, et al. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 95: 1735–1746.

6. Tran CP, Liu C, Yamashiro J, Reiter RE (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1: 113–121.

7. Ross S, Spencer SD, Lasky LA, Koeppen H (2001) Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis. Am J Pathol 158: 809–816.

8. Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, et al. (2002) Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunonjugate. Cancer Res 62: 2546–2553.

9. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, et al. (2001) Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 98: 2630–2633.

10. Leptin EJ, Leyton JV, Zhou Y, Olafeni T, Salazar FB, et al. (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 37: 1529–1538.

11. Zhang X, Wenhu S (2007) Prostate stem cell antigen (PSCA): mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer. Prostate 67: 1143–1151.

12. Moore ML, Teitel MA, Kim Y, Watabe T, Reiter RE, et al. (2006) Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 68: 119–131.

13. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE (2002) Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 16: 2323–2337.

14. Shi Y, Lee JS, Galvin KM (1997) Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta 1332: F49–66.

15. Deng Z, Cao P, Wan M, Sui G (2007) PIASy-mediated sumoylation of Yin Yang 1 expressing tumors. Eur J Nucl Med Mol Imaging 37: 1529–1538.

16. Seligson D, Hoovath S, Huerta-Yepes S, Hanna S, Garban H, et al. (2003) Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 27: 131–141.

17. Deng Z, Wan M, Cao P, Rao A, Cramer SD, et al. (2009) Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene 28: 3746–3757.

18. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, et al. (2007) Marine cell lines derived from Pem null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67: 6083–6091.

19. Horoszewicz JN, Leong SS, Kawinski E, Karr JP, Rosenfeld H, et al. (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809–1818.

20. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16–23.

21. DuBojBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379–387.

22. Hirai H, Sherr CJ (1996) Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol 16: 6457–6467.

23. Deora R, Rootma HJ, Miller JF, Cotter PA (2001) Diversity in the Bordetella virulence regulon: transcriptional control of a Bvg-intermediate phase gene. Mol Microbiol 40: 669–683.

24. Mishra D, Deora R (2005) Mode of action of the Bordetella BvgA protein: transcriptional activation and repression of the Bordetella bronchiseptica bvgA promoter. J Bacteriol 187: 6290–6299.

25. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K (2005) Ras-Raf-Ark signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 25: 220–232.

26. Heinemeyer T, Wingender E, Reuter I, Herrmann E, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362–367.

27. Watabe T, Lin M, Ide H, Donjacour AA, Gnuma GR, et al. (2002) Growth, differentiation, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A 99: 401–406.

28. Hyde-DeRuyser RP, Jennings E, Sherk T (1995) DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res 23: 4457–4465.

29. Gordon S, Akopian G, Garban H, Benavid B (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125–1142.

30. Thomas MJ, Seto E (1999) Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 236: 197–206.

31. Deng Z, Wan M, Sui G (2007) PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol 27: 3780–3792.

32. Dubez P, Wu H, Reiter RE, Witte ON (2001) Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 61: 326–3261.

33. Lieberthal JG, Kaminsky M, Parkhurst CN, Tanese N (2009) The role of YY1 in reduced H2Aphalpha gene expression in invasive human breast cancer cells. Breast Cancer Res 11: R42.

34. Tan DP, Nonaka K, Nuckolls GH, Liu YH, Maxson RE, et al. (2002) YY1 activates Msx2 gene independent of bone morphogenetic protein signaling. Nucleic Acids Res 30: 1213–1223.

35. Bahrenberg G, Brauers A, Joost HG, Sherk T (1995) DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res 23: 4457–4465.

36. Thomas MJ, Seto E (1999) Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 236: 197–206.